![](/img/cover-not-exists.png)
Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma
Lassen, U., Chinot, O. L., McBain, C., Mau-Sorensen, M., Larsen, V. A., Barrie, M., Roth, P., Krieter, O., Wang, K., Habben, K., Tessier, J., Lahr, A., Weller, M.Volume:
17
Language:
english
Journal:
Neuro-Oncology
DOI:
10.1093/neuonc/nov019
Date:
July, 2015
File:
PDF, 467 KB
english, 2015